– UK, Redcar – Nuformix plc (LON: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, today announced the appointment of Dr. Dan Gooding to its Board as an Executive Director, effective from 1 August 2022.
“I am pleased that Dan has agreed to join the board as an Executive Director. He brings significant history with Nuformix and experience to the table which will help facilitate the progression of our assets, and in particular our NXP002 programme. I believe that we now have a board and management structure appropriate for the Company’s needs in order to optimise value from its assets while maintaining tight control of costs. I look forward to providing further updates in due course as we progress.” said Board Chairman, Dr Julian Gilbert.
Concurrently, Dr. Julian Gilbert, current Non-executive Director, has been appointed to the role of Non-Executive Chairman.
About Dr. Daniel Gooding
Dr. Dan Gooding was a co-founder of Nuformix and the Company’s CEO until June 2020. He instigated the Company’s NXP002 programme as an inhaled therapy for the treatment of Idiopathic Pulmonary Fibrosis and has been acting as a consultant to the Company since March 2022. He has over 22 years of experience in commercialization and business development within the pharmaceutical industry, having received his Ph.D. in chemistry from Leeds University. Dan began his career in commercial roles with pharmaceutical excipients companies including FMC and Dow Corning. At Accelrys Ltd, Dan was responsible for sales across the UK and Southern Europe, leading business development within the emerging nanotechnology, drug delivery, and formulation sectors, achieving licensing deals with Johnson & Johnson and AstraZeneca. Since June 2020, Dan has remained close to the fields of fibrosis, oncology, and drug repurposing. Dan supported the management team of Qureight Limited in securing funding and establishing this Cambridge-based start-up, which develops AI-based image processing methods for measuring disease progression and drug response for patients with fibrotic lung diseases including IPF. Dan has also cofounded TRx Biosciences, a company developing new oral therapies using a novel targeted delivery technology to improve the treatment of various cancers and CNS diseases.
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing, and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route, or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
For more information: https://www.nuformix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
